Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
No pe ratio figures for Wave Life Sciences
Wave Life Sciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?